
Opinion|Videos|August 5, 2024
Key Patient Factors in Determining an Optimal Biologic Therapy
An expert rheumatologist highlights the billing process for patients receiving biologic therapies, as well as a study that highlights patient reported outcomes in patients with inflammatory arthritis utilizing intravenous biologics.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What is the difference in the billing process with IV and subQ therapies? What are the pros and cons of each?
- Patient reported outcomes have been assessed for patients with inflammatory arthritis utilizing IV biologics. What did this study demonstrate and does it impact your clinical practice?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare Part D redesign reshapes market
2
Rural health is ailing. Is $50 billion enough to heal it?
3
The sleep doctor who lives with a disorder he treats
4
A conversation with Tiffany Phung, Pharm.D., CSP, about how patient outcomes drive specialty pharmacy strategy
5




















